Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/17/2005US20050256029 Administering aminobutyric acid receptor modulators such as 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-5-hydroxy-2-oxohexyl) -1-isoindolinone for prophylaxis of nervous system and developmental disorders; speech therapy
11/17/2005US20050256028 Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255480 A norovirus-permissive cell culture, including dendritic- and macrophage-lineage cells and macrophages having a deficiency in a cellular anti-viral pathway such as a STAT-1-dependent pathway, an interferon receptor-dependent pathway, or a PKR-dependent pathway infected with a norovirus
11/17/2005US20050255251 Composition, method of making, and treatment of wood with an injectable wood preservative slurry having biocidal particles
11/17/2005US20050255173 Anticancer composition
11/17/2005US20050255164 Solid nano pharmaceutical formulation and preparation method thereof
11/17/2005US20050255162 Hydrophobic biomolecular structure
11/17/2005US20050255161 Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
11/17/2005US20050255158 Combinations of HMG-COA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
11/17/2005US20050255157 Sustained release, mucoadhesive vaginal pharmaceutical compositions
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255155 Modified release cilostazol compositions
11/17/2005US20050255154 Method and composition for treating rhinitis
11/17/2005US20050255153 Mixture of deprotonatable lipid, such as polyoxyethylene glycol or polyamide lipid with buffered aqueous solution of charged drug
11/17/2005US20050255151 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
11/17/2005US20050255150 Wound treatment patch for alleviating pain
11/17/2005US20050255143 Method of use of carboxylated polysaccharides topically on the eyeball
11/17/2005US20050255138 Active agent transport systems
11/17/2005US20050255133 Topical composition for acne treatment
11/17/2005US20050255131 Clindamycin compositions and delivery system therefor
11/17/2005US20050255130 Retinoid solutions and formulations made therefrom
11/17/2005US20050255126 biologically pure strain of Aureobasidium pullulans isolated from a food source; culturing in a medium containing saccharides as a carbon source; has resistance to the antibiotic cycloheximide
11/17/2005US20050255124 HCV E1E2 vaccine compositions
11/17/2005US20050255121 An immunogenic or antigenic agent and a gelling agent and mucoadhesive or bioadhesive such as carboxymethyl cellulose for intradermal delivery; enhanced efficacy allows lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations
11/17/2005US20050255113 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
11/17/2005US20050255111 Use of an inhibitor or antagonist against tissue factor
11/17/2005US20050255103 Remedy for lung cancer
11/17/2005US20050255100 Isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5; tumor necrosis factor blocking agent; cyclosporine immunosuppressant; antibiotic; anti-inflammatory; graft versus host disease, viral infection, cancer, leukemia, immunodeficiency, autoimmune disorder
11/17/2005US20050255099 Antigenic fusion protein carrying Galalpha 1,3Gal epitopes
11/17/2005US20050255096 Combination treatment for acute myocardial infarction
11/17/2005US20050255087 Adeno-associated virus vectors
11/17/2005US20050255085 Prevention of recurrence and metastasis of cancer
11/17/2005US20050255082 Polymeric coupling agents and pharmaceutically-active polymers made therefrom
11/17/2005US20050255081 Stabilizers for hydrolyzable organic binders
11/17/2005US20050255080 Magic bullets and anti - slip
11/17/2005US20050255079 Polymeric coupling agents and pharmaceutically-active polymers made therefrom
11/17/2005US20050255076 Therapeutic cream for dermatitis
11/17/2005US20050255071 Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
11/17/2005US20050255059 Personal care compositions and methods regulating mammalian hair growth
11/17/2005US20050255050 Powder formulations for inhalation, comprising enantiomerically pure beta agonists
11/17/2005US20050255049 Formoterol and mometasone aerosol formulations
11/17/2005US20050255048 Sprayable formulations for the treatment of acute inflammatory skin conditions
11/17/2005US20050255039 Gel injection treatment of breast, fibroids & endometrial ablation
11/17/2005DE20122471U1 New deuterated porphobilinogen derivatives useful as therapeutic agents, in association with photodynamic procedures or gamma radiation, in the treatment of tumors and as diagnostic agents in the diagnosis of tumors
11/17/2005DE10392697T5 Herstellung und Standardisierung von immunmodulierenden Peptid-verknüpften Glucanen mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor Preparation and standardization of immunomodulating peptide-linked glucans with detectable oral absorbability from Coriolus Versicolor
11/17/2005DE102004020186A1 Heterocyclylessigsäuren als Inhibitoren von TAFla Heterocyclylessigsäuren as inhibitors of TAFIa
11/17/2005DE102004019916A1 Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster Against abuse secured medicated plaster
11/17/2005DE102004019736A1 Use of a calcitonin gene related peptide antagonist and a serotonin reuptake inhibitor to treat headaches, migraine and cluster headaches
11/17/2005DE102004010547A1 Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz Oligoribonucleotides for the treatment of irritative and / or inflammatory skin lesions by RNA interference
11/17/2005CA2777216A1 Process for preparing atazanavir bisulfate and novel forms
11/17/2005CA2774146A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months
11/17/2005CA2568241A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
11/17/2005CA2566699A1 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
11/17/2005CA2566433A1 Therapeutic agent for bh4-responsive hyperphenylalaninemia
11/17/2005CA2566431A1 Process for the preparation of telmisartan
11/17/2005CA2566426A1 Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
11/17/2005CA2566398A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
11/17/2005CA2566393A1 Cla-enriched milkfat and uses thereof
11/17/2005CA2566339A1 The treatment of respiratory disease
11/17/2005CA2566228A1 Method of tonic treatment with oxyphenbutazone derivatives
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2566112A1 Carbamate linked macrolides useful for the treatment of microbial infections
11/17/2005CA2566098A1 Therapeutic agent for keratoconjunctival disorder
11/17/2005CA2566096A1 Piperazine derivatives of alkyl oxindoles
11/17/2005CA2566092A1 Crystalline forms of duloxetine free base
11/17/2005CA2566085A1 Ester linked macrolides useful for the treatment of microbial infections
11/17/2005CA2566083A1 Antifatigue composition
11/17/2005CA2566080A1 Kit for treatment of cancer
11/17/2005CA2566041A1 T-type calcium channel splice variant compositions and methods
11/17/2005CA2565996A1 Combination of atypical antipsychotics and 5-ht1b receptor antagonists
11/17/2005CA2565913A1 Composition for stimulating bone growth and differentiation and method for isolating same
11/17/2005CA2565878A1 Pharmaceutical composition for prevention or treatment of lipid metabolism disorder
11/17/2005CA2565854A1 Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
11/17/2005CA2565843A1 Novel compounds of proline and morpholine derivatives
11/17/2005CA2565721A1 Diindolymethane formulations for the treatment of leiomyomas
11/17/2005CA2565695A1 Certain chemical entities and compositions for use in the treatment of a cellular proliferative disease or disorder
11/17/2005CA2565632A1 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
11/17/2005CA2565630A1 Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
11/17/2005CA2565616A1 Pyrroloquinoline quinone drugs for treatment of cardiac injury
11/17/2005CA2565588A1 Crystalline forms of 9-(s)-erythromycylamine
11/17/2005CA2565544A1 Benzonitrile derivatives to treat musculoskeletal frailty
11/17/2005CA2565459A1 Anti-excitotoxic sustained release intraocular implants and related methods
11/17/2005CA2565387A1 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
11/17/2005CA2565384A1 Phospholipase inhibitors localized in the gastrointestinal lumen
11/17/2005CA2565367A1 Dihydrobenzothiophenes
11/17/2005CA2565363A1 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity
11/17/2005CA2565295A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months
11/17/2005CA2565285A1 Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
11/17/2005CA2565250A1 Cysteamines for treating complications of hypercholesterolemia and diabetes
11/17/2005CA2565221A1 Biodegradable intravitreal tyrosine kinase inhibitors implants
11/17/2005CA2565218A1 Compounds and compositions for treatment of cancer
11/17/2005CA2565214A1 (4, 5, 6, 7-tetrahydro-1-h-indol-7-yl) acetic acid derivatives for treatment of alzheimer's disease
11/17/2005CA2565183A1 Topical preparation containing ambroxol
11/17/2005CA2565170A1 The treatment of childhood asthma
11/17/2005CA2565094A1 Compounds with activity at estrogen receptor
11/17/2005CA2565079A1 Methods for treating arthritic conditions in dogs
11/17/2005CA2565061A1 Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents
11/17/2005CA2564986A1 Pyrrole or imidazole amides for treating obesity
11/17/2005CA2564980A1 Novel beta agonists, method for producing the same and their use as drugs
1 ... 4466 4467 4468 4469 4470 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 ... 7860